Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

EGFR-Mutant Advanced NSCLC: Global Insights on Testing and Treatment Planning
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: July 29, 2021 Expiration: July 28, 2022
Start Activity
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca
Edward S. Kim, MD, FACP, FASCO
Luis Paz-Ares, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC, including the use of tissue-based and blood-based biomarker testing for evaluation of EGFR mutation status in newly diagnosed patients and those with acquired resistance following EGFR TKI therapy

  • Compare available efficacy and safety data of systemic EGFR-targeted therapies throughout the continuum of EGFR mutation–positive NSCLC from the first-line setting to the second-line setting and beyond (including outcomes by type of EGFR mutation)
  • Plan sequential therapy based on an understanding of the mechanisms of resistance following EGFR TKI treatment, including the incidence of T790M and amplification of MET
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for EGFR mutation–positive NSCLC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Edward S. Kim, MD, FACP, FASCO

Physician-in-Chief
Senior Vice President
City of Hope Orange County
Irvine, California

Edward S. Kim, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, G1 Therapeutics, and Genentech.
Luis Paz-Ares, MD, PhD

Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

Luis Paz-Ares, MD, PhD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Amgen, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Ipsen, Janssen/GlaxoSmithKline, Lilly, Merck Serono, MSD, Mirati, Novartis, Pfizer, PharmaMar, Roche, Sanofi, Takeda, and Tesaro; has received funds for research support from AstraZeneca, Bristol-Myers Squibb, and PharmaMar; and is a founder/board member of Altum Sequencing and Genomica.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-e Xu, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, nurses, and other providers who care for patients with NSCLC

Goal

The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with EGFR Mut+ NSCLC.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 29, 2021, through July 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

EGFR-Mutant Advanced NSCLC: Global Insights on Testing and Treatment Planning
  • CME
  • CE

Loading...

Watch this on-demand webcast capturing a live CCO webinar to gain global perspectives on the optimal care of patients with advanced EGFR-mutated NSCLC, including guidance on testing for EGFR mutations, future directions, and new data from ASCO 2021.

Edward S. Kim, MD, FACP, FASCO
Luis Paz-Ares, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: July 29, 2021 Expiration: July 28, 2022

Related Content

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Results from phase III ATLANTIS trial of lurbinectedin plus doxorubicin in patients with relapsed small-cell lung cancer (SCLC), from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021

CheckMate 9LA analysis of nivolumab plus ipilimumab plus chemotherapy in advanced NSCLC with brain metastases, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 17, 2021
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue